evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).
Autor: | Mayer, Erica L., Tolaney, Sara M., Brufsky, Adam, Gradishar, William John, Jhaveri, Komal L., Martin, Miguel, Moscetti, Luca, Schneeweiss, Andreas, Vidal, Gregory A., Cortazar, Patricia, Feldman, Merilin, Day, Bann-mo, Rugo, Hope S. |
---|---|
Zdroj: | Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS1119-TPS1119, 1p |
Databáze: | Supplemental Index |
Externí odkaz: |